Overview

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single and multiple ascending doses in healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca